Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.47 USD | -1.22% | -6.37% | -37.25% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.25% | 186M | |
+9.48% | 222B | |
+13.72% | 195B | |
+23.79% | 148B | |
+33.39% | 113B | |
+4.22% | 66.45B | |
+15.59% | 53.11B | |
+3.16% | 50.03B | |
-4.35% | 38.8B | |
-1.27% | 34.85B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating